Anti-IgE therapy for children and adolescents

被引：0
作者：
Wahn, U. [1 ]
Hamelmann, E. [1 ]
机构：
[1] Charite, Klin Padiat Schwerpunkt Pneumol & Immunol, D-13353 Berlin, Germany
来源：
MONATSSCHRIFT KINDERHEILKUNDE | 2007年 / 155卷 / 02期
关键词：
IgE; bronchial asthma; complex allergies; omalizumab; anti-IgE;
D O I：
10.1007/s00112-006-1455-8
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Immunoglobulin E (IgE) plays a key role in mediating allergic reactions to food and environmental allergens, which are relevant for the expression of allergic symptoms of the airways (rhinoconjunctivitis, bronchial asthma), the skin (urticaria, atopic dermatitis), as well as the gastrointestinal tract (food allergens). The recombinant humanized antibody omalizumab, which became available in Germany in 2005 for the treatment of severe allergic asthma for children aged 12 years and above, has proved its therapeutic efficacy for special cases,as well as its safety in all age groups. In addition to bronchial asthma, anti-IgE offers interesting perspectives for the treatment of complex allergic diseases which have a strong impact on quality of life and have so far been difficult to control.
引用
收藏
页码：134 / 137
页数：4
相关论文
共 19 条
[1]   Omalizumab-induced reductions in mast cell FcεRI expression and function [J].
Beck, LA ;
Marcotte, GV ;
MacGlashan, D ;
Togias, A ;
Saini, S .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (03) :527-530
[2]   The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma [J].
Bousquet, J ;
Cabrera, P ;
Berkman, N ;
Buhl, R ;
Holgate, S ;
Wenzel, S ;
Fox, H ;
Hedgecock, S ;
Blogg, M ;
Della Cioppa, G .
ALLERGY, 2005, 60 (03) :302-308
[3]   The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [J].
Buhl, R ;
Hanf, G ;
Solèr, M ;
Bensch, G ;
Wolfe, J ;
Everhard, F ;
Champain, K ;
Fox, H ;
Thirlwell, J .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (05) :1088-1094
[4]   Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma [J].
Buhl, R ;
Solèr, M ;
Matz, J ;
Townley, R ;
O'Brien, J ;
Noga, O ;
Champain, K ;
Fox, H ;
Thirlwell, J ;
Della Cioppa, G .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (01) :73-78
[5]   Effect of omalizumab on symptoms of seasonal allergic rhinitis - A randomized controlled trial [J].
Casale, TB ;
Condemi, J ;
LaForce, C ;
Nayak, A ;
Rowe, M ;
Watrous, M ;
McAlary, M ;
Fowler-Taylor, A ;
Racine, M ;
Gupta, N ;
Fick, R ;
Della Cioppa, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (23) :2956-2967
[6]   Anti-IgE as a mast cell-stabilizing therapeutic agent [J].
Chang, TW ;
Shiung, YY .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (06) :1203-1212
[7]   Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma [J].
Djukanovic, R ;
Wilson, SJ ;
Kraft, M ;
Jarjour, NN ;
Steel, M ;
Chung, KF ;
Bao, WB ;
Fowler-Taylor, A ;
Matthews, J ;
Busse, WW ;
Holgate, ST ;
Fahy, JV .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (06) :583-593
[8]   The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects [J].
Fahy, JV ;
Fleming, HE ;
Wong, HH ;
Liu, JT ;
Su, JQ ;
Reimann, J ;
Fick, RB ;
Boushey, HA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (06) :1828-1834
[9]   From IgE to Anti-IgE: Where do we stand? [J].
Hamelmann, E ;
Rolinck-Werninghaus, C ;
Wahn, U .
ALLERGY, 2002, 57 (11) :983-994
[10]   Is there a role for anti-IgE in combination with specific allergen immunotherapy? [J].
Hamelmann, Eckard ;
Rolinck-Werninghaus, Claudia ;
Wahn, Ulrich .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 3 (06) :501-510
12